🇺🇸 FDA
Pipeline program

Nimotuzumab combined with chemoradiotherapy

PRO-A

Phase 2 small_molecule active

Quick answer

Nimotuzumab combined with chemoradiotherapy for Pancreatic Cancer Non-resectable is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Pancreatic Cancer Non-resectable
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials